243 related articles for article (PubMed ID: 33198803)
1. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
2. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
4. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
6. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
7. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
Kim CY; Kim YC; Oh JH; Kim MH
Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
[TBL] [Abstract][Full Text] [Related]
10. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
11. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
[TBL] [Abstract][Full Text] [Related]
13. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
14. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
Yang S; Lee JY; Hur H; Oh JH; Kim MH
BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
[TBL] [Abstract][Full Text] [Related]
16. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
Wang L; Zhang X; Wang ZY
Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
[TBL] [Abstract][Full Text] [Related]
17. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
[TBL] [Abstract][Full Text] [Related]
18. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
19. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer.
Xie Y; Han X; Yu J; Yuan M; Yan Y; Qin J; Lan L; Wang Y
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18103-18117. PubMed ID: 37999751
[TBL] [Abstract][Full Text] [Related]
20. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]